Keeping up with the latest developments in vaccine clinical trials is essential to ensuring positive patients outcomes. Continuous trial-based research advances knowledge of vaccine safety, effectiveness, and responses to emerging variants. Data gathered from clinical trials helps clinicians deliver evidence-based guidance, anticipate patient questions, help answer those questions, and overall make better treatment choices.
Maintaining awareness of new vaccine candidates and study outcomes enables early adoption into clinical practice and preventive strategies. The following clinical trials are all active and no longer recruiting. The selection represents a small sampling of the many ongoing, phase 3 clinical trials currently taking place. Estimated completion times vary and are outlined in the following table.
| Study Title | Phase | Enrollment | Start Date | Estimated Primary Completion |
|---|---|---|---|---|
| A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults (PISSARRO) | 3 | 526 | April 2025 | September 2025 |
| A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age | 3 | 7454 | October 2021 | April 2026 |
| A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old | 3 | 60 | March 2025 | May 2026 |
| Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older | 3 | 240 | April 2025 | May 2026 |
| Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) | 3 | 6300 | February 2024 | May 2026 |
| Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults | 3 | 30 | February 2025 | October 2026 |
Active, Phase 3 Clinical Trials
A Study to Evaluate the Safety and Immunogenicity of RSVpreF Co-administered With Herpes Zoster Vaccine in Adults (PISSARRO)
- Pfizer
- Goal: To learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.
- Interventions: Respiratory syncytial virus perfusion F subunit vaccine, HZ/su vaccine.
- Study Details
- Source
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
- ModernaTX
- Goal: To evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety and reactogenicity of mRNA-1647 vaccine in all participants.
- Interventions: mRNA-1647, placebo
- Study Details
- Source
A Trial of a Norovirus G1.1 and G2.4 Vaccine Administered Orally to Healthy Participants Aged ≥ 18 Years and ≤ 80 Years Old
- Vaxart
- Goal: To determine the safety and immunogenicity of low and high dose regimens of a next generation norovirus bivalent G1.1 and G2.4 vaccine candidate in healthy participants.
- Interventions: VXA-G1.1-NN, VXA-G2.4-NS, VXA G1.1 NN-T, VXA G2.4 NS-T
- Study Details
- Source
Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older
- Sanofi
- Goal: to investigate the safety and immunogenicity of different doses (high, medium and low) of a second generation structurally designed (SD2) H5 messenger ribonucleic acid (mRNA) vaccine against pandemic H5 influenza virus (pandemic flu H5 hemagglutinin (HA) mRNA SD2) in healthy younger and older adults.
- Interventions: Pandemic flu H5 HA mRNA SD2 vaccine, placebo
- Study Details
- Source
Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL)
- Sanofi Pasteur
- Goal: The purpose of the study is to evaluate the efficacy, immunogenicity, and safety of Respiratory Syncytial Virus Toddler (RSVt) vaccine administered by intranasal route compared to placebo.
- Interventions: RSVt Vaccine, placebo
- Study Details
- Source
Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults
- National Institute of Allergy and Infectious Diseases (NIAID)
- Goal: The primary objective is to assess the safety and reactogenicity of 4 mcg versus 10 mcg dose of the HydroVax-001B WNV vaccine administered intramuscularly (IM) on Days 1, 29 and 181.
- Interventions: HydroVax-001B WNV, placebo, sodium chloride 0.9%
- Study Details
- Source
Sign up for alerts and stay informed on the latest published guidelines.
Copyright © 2025 Guideline Central, all rights reserved.